Printer Friendly

Celera Genomics and Applied Biosystems Groups Announce Computational Infrastructure Upgrade.

Business Editors & Health/Medical Writers

BIOWIRE2K

FOSTER CITY, Calif. & ROCKVILLE, Md.--(BUSINESS WIRE)--Sept. 26, 2002

Therapeutics Focus, New Online Applications Call for

Broader Range of Technological Capabilities

Celera Genomics Group (NYSE:CRA) and Applied Biosystems Group (NYSE:ABI), Applera Corporation businesses, today announced that they will replace and upgrade the computational infrastructure supporting Celera's drug discovery and development efforts and the Knowledge Business of Applied Biosystems.

IBM (NYSE: IBM) will provide the computational capacity server hardware, operating system and conversion services for the effort. EMC Corporation (NYSE: EMC) will supply the automated networked storage systems and software, as well as data migration services. Celera and Applied Biosystems selected IBM and EMC as the "vendors of choice," balancing the performance, stability, flexibility and service needed to build one of the world's largest industrial high-performance computing centers. All computational infrastructure replacements and upgrades will be implemented at the Rockville, Maryland, site. Financial terms were not disclosed.

"After carefully assessing the future computing needs of these businesses, we completed a thorough analysis of the computing technologies and players - and these companies offered the right solutions to move forward through the next phase of Celera's drug discovery efforts and the Applied Biosystems' service and product offerings," said Tama Olver, Vice President and Chief Information Officer, Applera Corporation.

Building upon its ground-breaking heritage in applying large-scale computing to challenging life sciences problems, Celera will combine the next-generation computational and information storage technologies for better access to and management of its proteomics, genomics, bioinformatics and medicinal chemistry platforms to accelerate the drug discovery process.

"Celera's goal is to maintain cutting-edge computing capabilities with a platform that has the flexibility and capacity for a wide range of discovery and development activities. Together, the technologies and services to be provided by IBM and EMC will support our dynamic scientific environment," said Robert Booth, Senior Vice President, Research & Development, Celera Genomics.

Applied Biosystems plans to create a common platform between the Celera Discovery System (CDS), its life sciences e-commerce applications, and other products and services based on the IBM and EMC solutions. Ultimately, the expanded e-commerce portal to be developed by Applied Biosystems may be used by scientists to apply the genomic information within CDS more intelligently to their biological experiments.

"Applied Biosystems' CDS offerings, genomic assays and other products and services will be served by the new computational infrastructure in Rockville," said Applied Biosystems' Deborah Smeltzer, Vice President of the Knowledge Business. "It offers the latest in current, mainstream technology and at an excellent value."

About Applera Corporation

Applera Corporation comprises two operating groups. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomics, bioinformatics, and genomics capabilities to identify and validate drug targets and diagnostic marker candidates, and to discover and develop novel therapeutic candidates. Its Celera Discovery System(TM) online platform, marketed exclusively through the Knowledge Business of Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at www.applera.com, or by telephoning 800.762.6923.

Copyright(c)2002. Applera Corporation. All Rights Reserved. Applied Biosystems, Celera, Celera Diagnostics and Celera Genomics are registered trademarks of Applera.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 26, 2002
Words:630
Previous Article:Weider Announces Fiscal 2003 First Quarter Results.
Next Article:Cegedim Expands Offerings to Central and South America by Announcing the Acquisition of MS Mexicana.
Topics:


Related Articles
Celera Genomics Appoints John Reynders as Vice President, Information Systems.
PHARMACEUTICAL COMPANIES USE GENOMIC INFORMATION IN R&D.
Otsuka Pharmaceutical Co., Ltd. Subscribes to Celera Discovery System.
Celera Genomics and Celera Diagnostics to Webcast Investor Meeting.
Applied Biosystems Group and Celera Genomics Group Second Quarter FY 2002 Financial Results Scheduled for Release January 23, 2002.
UK Medical Research Council and Celera Sign Agreement on Access to Genomic Database.
Applied Biosystems Group and Celera Genomics Group Third Quarter FY 2002 Financial Results and Conference Call Scheduled for Release April 25, 2002.
Celera Genomics and Applied Biosystems Select IBM Supercomputers and Services for Drug Discovery and Knowledge Businesses.
Celera Genomics and Applied Biosystems Groups Select EMC for Automated Networked Storage.
Applied Biosystems Receives Adverse Jury Verdict Relating to Discontinued Operations.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters